|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
06660 AIM VACCINE
Nominal 
7.970 +0.140 (+1.788%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 537,178 | -0.609% | 1,187,468 | 1,264,073 | 1,570,129 | 1,637,970 |
| Cost of Sales | (148,888) | 38.087% | (286,452) | (236,414) | (275,429) | (283,882) |
| Gross Profit | 388,290 | -10.253% | 901,016 | 1,027,659 | 1,294,700 | 1,354,088 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | (61,091) | -- | -- | -- | |
| Change in FV & Impairment on Others | (3,857) | 5.095% | (1,727,854) | (27,215) | (7,981) | (826) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (159,310) | -48.590% | (2,270,645) | (434,165) | (606,703) | 485,886 | |
| Taxation | 14,046 | -73.219% | 320,404 | 203,535 | (69,170) | (85,472) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 6,010 | -14.909% | 649,236 | (88,971) | (16,901) | (21,127) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (139,254) | -44.380% | (1,301,005) | (319,601) | (692,774) | 379,287 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 25,642 | 86.841% | 33,125 | 14,999 | (74) | 5,005 |
| Depreciation & Amortisation | 92,282 | 1.600% | 174,697 | 166,441 | 144,291 | 128,342 |
| Directors' Emoluments | -- | -- | 8,035 | 78,463 | 902,616 | 4,710 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -11.000 | -47.619% | -107.000 | -27.000 | -60.000 | -- |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | -- | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.137) | (0.092) | 0.080 | -- |
| NBV per share ($) | 2.893 | -- | 3.008 | 4.096 | -- | -- |
| Remarks: | Real time quote last updated: 08/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -139,254,000 |
| %Change | -44.380% |
| EPS / (LPS) | RMB -0.110 |
| NBV Per Share (¥) | RMB 2.893 |